Abstract: The present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt thereof: and to pharmaceutical compositions comprising the compound. In Formula (I), R3 is selected from the group consisting of: wherein rings W, X, Y and Z may relate to various heterocyclic, heteroaryl, cycloalkyl, cycloalkenyl, and/or aryl rings. The present invention also relates to uses of the compounds in treating a disease, disorder or condition caused by viral infection.

Abstract: Ligands of complement receptor 3, including ligands of the I domain of the alpha subunit of this receptor, are useful in methods, compositions and articles/devices for inhibiting the interaction of pathogens to a complement receptor 3-expressing cell and for treating or inhibiting the development of infections caused by such pathogens.

Abstract: This invention relates, inter alia, to an immunogenic fragment of a Neisserial Heparin Binding Antigen (NHBA) protein of Neisseria gonorrhoeae (SEQ ID NO: 1) for the prevention and treatment of Neisseria gonorrhoeae or gonococcal- or meningococcal-associated diseases and conditions. In some embodiments, the immunogenic fragment corresponds to a C-terminal fragment of the protein (SEQ ID NO: 2).

Abstract: This invention relates generally to polynucleotides, polypeptides, compositions, methods and uses for eliciting an immune response to Neisseria, methods for immunizing a subject against a Neisseria infection, and methods for preventing and/or treating a Neisseria infection in a subject. More particularly, the invention relates to antigenic Neisseria polypeptides and encoding polynucleotides, and related uses and methods, including use for preparing compositions and medicaments for eliciting an immune response to Neisseria, for immunizing a subject against a Neisseria infection, and for preventing and/or treating a Neisseria infection in a subject. The invention also relates to methods for producing therapeutic anti-Neisseria antigen-binding molecules, and therapeutic uses of those antigen-binding molecules.

Abstract: A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 peptide may be particularly efficacious. An S2 peptide or variant may be co-administered with the modified p145 peptide to enhance the immune response.

Abstract: The present invention relates to a rehabilitation system for rehabilitating a person with a neurological condition, such as a spinal cord injury (SCI). The system includes exercise equipment for enabling the person to exercise. One or more sensors are provided for sensing information from the person during exercise. The system also includes a model of the exercising person configured to receive the sensed information from the sensors and generate electrical stimulation for the person. Advantageously, the personalized computer model may be used to generate suitable electrical stimulation for the person, and avoid excessive stresses on the person which can lead to the fracturing of bones.

Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of NETs in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating NET mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of NET mediated ailments. For example, the present invention relates to methods and uses of ?-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.

Abstract: This invention relates to a codon deoptimized severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) genome. In particular, embodiments of the invention concern a vaccine comprising live attenuated SARS-COV-2 comprising a partly codon deoptimized viral genome, SARS-COV-2 comprising a partly codon deoptimized viral genome, as well as their use in methods of treatment and prevention of viral infection. The ORF1a region of the viral genome has been codon deoptimized.

Abstract: The present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and to pharmaceutical compositions comprising the compound. In Formula (I), rings W, X, Y and Z may relate to various heterocyclic, heteroaryl, cycloalkyl, cycloalkenyl, and/or aryl rings. The present invention also relates to uses of the compounds in treating a disease, disorder or condition caused by viral infection.

Abstract: The present invention relates to a method for producing a sport beverage, comprising the steps of providing malt and/or unmalted grains, providing mashing liquor produced from spent grains, processing the malt and the mashing liquor to obtain a wort, fermenting the wort by using a yeast and optionally, blending with flavour(s) and/or vitamin(s); and/or adding of sugar(s). The present invention further relates to a sport beverage obtained by said method, wherein said sport beverage is non-alcoholic or has an alcohol content of less than about 1.2 vol-%, preferably less than about 0.5 vol-%. The present invention also relates to the use of the sport beverage before and/or after physical activities.

Abstract: A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 peptide may be particularly efficacious. An S2 peptide or variant may be co-administered with the modified p145 peptide to enhance the immune response.

Abstract: Disclosed are compositions for stimulating a protective or therapeutic immune response to an apicomplexan parasite such as those from the Plasmodium or Babesia genus. More particularly, the compositions comprise a soluble parasite extract. The extract may be free of red blood cell components and/or contained in or associated with a particle such as a liposome. The compositions and methods disclosed herein are particularly useful in the prevention and treatment of parasitic diseases.

Abstract: The present invention relates to a three-dimensional multiphasic synthetic tissue scaffold comprising first, second and third compartments, wherein: each said compartment comprises distinct microstructural, and/or chemical, and/or mechanical properties, and is connected with at least one other compartment of the scaffold via a continuous interface; the tissue scaffold is porous; and the external morphology of the tissue scaffold mimics that of a mammalian joint or a component thereof. The invention further relates to a method for producing the three dimensional multiphasic synthetic tissue scaffold using a polymeric material, the method comprising using a three-dimensional (3D) bioprinter to print the tissue scaffold by continuously deposit the polymeric material onto a platform until the tissue scaffold is produced in its entirety.

Abstract: A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A Streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 5 peptide may be particularly efficacious. An S2 peptide or variant may be co-administered with the modified p145 peptide to enhance the immune response.

Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRO). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of ?-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g.

Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of ?-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.

Abstract: A securement device for securement of a catheter connecting assembly to a body of a patient wherein the catheter connecting assembly includes two or more ports adapted to be coupled with the catheter, each port being formed by a respective port body wherein the ports are adapted to be fluidly coupled to a catheter hub of a catheter, the securement device comprising: a base having a continuous top surface and a continuous bottom surface wherein at least a portion of the top surface comprises an antimicrobial layer and wherein at least a portion of the bottom surface comprises an adhesive for attachment of the base to the body of the patient and wherein the base is dimensioned to prevent direct contact between said ports and body of the patient; and one or more retention formations located on the top surface of the base for receiving and retaining at least a portion of a housing comprising said one or more port bodies adapted to be coupled with a terminal end of the catheter.

Abstract: A sensing platform comprises a semiconductor junction, in particular a SiC/Si heterojunction, with a pair of electrodes located on a surface of an upper layer of the semiconductor junction in a spaced apart relationship. The sensing platform comprises a light source above the surface of the upper layer to illuminate a part of the surface of the semiconductor junction comprising at least part of one of the electrodes to create a lateral potential gradient between the pair of electrodes through the photovoltaic effect in the semiconductor. Parameters, such as force and temperature, are detected based on measuring a change in electrical resistance of the semiconductor material due to the piezoresistive effect and/or the thermoresistive effect. An external potential difference can be applied between the pair of electrodes to create a tuning current to modulate the piezoresistive and thermoresistive effects in the semiconductor junction.

Abstract: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I) In which R3 is selected from the group consisting of optionally substituted N-linked naphthotriazole, optionally substituted N-linked indazole, and certain N-linked triazoles. The present invention also relates to uses of the compounds in treating a disease, disorder or condition caused by viral infection, and pharmaceutical compositions comprising the compounds.

Abstract: Apicomplexan parasites or red blood cells infected with apicomplexan parasites are administered to an animal in combination with a delayed death agent that initially allows parasite replication but subsequently kills the apicomplexan parasites. This allows the elicitation of an immune response by the animal while preventing the parasites producing a serious infection of the animal. The apicomplexan parasites may be malaria or babesia parasites. The delayed death agent may be a tetracycline class antibiotic, a macrolide antibiotic or a lincosamide antibiotic.